Check Out Boston Scientific’s Q4 And 2021 Financial Results

Boston Scientific has 3 subsidiaries: MedSurg, Rhythm and Neuro, and Cardiovascular. It develops devices for almost all areas of medicine: for the treatment and diagnosis of gastrointestinal, pulmonary, urological, gynecological, cardiac, and venous diseases. This company, which has been on the market for over 40 years, is valued at $61.987 billion. According to the 5-day chart, BSX’s price rose by $0.76 to $43.79 on January 27. The next day, it dipped 4.6%. However, the worth surged to $43.48 before the close of the last trading session.

According to the Boston Scientific Corporation (BSX) Q4 and 2021 financial report, net sales popped to $3.127 billion in three months and $11.888 billion in a year. GAAP net income was $80 million in Q4, while for the year this figure is $985 million. The company also shared important achievements in the field of medicine, such as the launch of a MODULAR ATP clinical trial, good results from another clinical trial, the launch of a limited number of AXIOS™ Stent in the Chinese market, and much more.